MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in
combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin
and cytarabine as a possible treatment for the patient AML.